About LCGC

helps bridge the gap between leads discovery research in Pharma and Academia through Double-Blinded Drug Discovery (DBD2)®, a protected open-innovation framework where both clients' intellectual property and privacy are protected through LCGC's proprietary systems. Utilizing a novel, patented automated repository system, proprietary software and orthogonal library-compression technology, LCGC distributes small-molecule libraries from major pharmaceutical companies to principal investigators in academia to validate novel biological targets for drug discovery to treat cancer and other diseases having unmet medical need.

LCGC facilitates information flow between clients, stepping back when a 'drug hit' of interest to both clients leads to mutual agreement on R&D investment to the non-profit client for further development of the pharmaceutical compound. Chemical collections received by the non-profit client can also be formatted to include LCGC's own 104,000-chemical library, which permits the client to capture IP and publication opportunities even if a pharmaceutical 'hit' is not revealed.

LCGC's leadership and management teams are dedicated to stewarding productive public/private partnering relationships in drug discovery. Please contact us for a more personalized introduction to our services.

 

Management

Melvin Reichman, PhD

Melvin Reichman, PhD

Founder, President and Chief Scientific Officer

Dr. Reichman has a Ph.D. in Neuroscience from the University of Rochester Center for Brain Research. His areas of specialty include behavioral psychopharmacology, receptor biology and enzymology, in vitro biochemical pharmacology and nuclear receptors. Dr. Reichman has held several leadership positions in pharma, most notably for GD Searle, Berlex Biosciences, Ligand Pharmaceuticals, Oncogene Science, and DuPont. At each company, Dr. Reichman has significantly improved the efficiency and productivity of new leads discovery and the progression of HTS hits to lead candidates. He is an acknowledged expert in automation and technology deployment for pharmaceutical research and development. Dr. Reichman has co-authored 26 publications in the field and has given dozens of invited talks on all aspects of drug discovery from concept to clinic.

 

Preston Scott Donover

Preston Scott Donover

Operations Manager, Research Laboratory Associate

Mr. Donover is a graduate of Oberlin College with a Bachelor of Arts degree. He joined LCGC from Dr. George Prendergast's laboratory at LIMR, previously of DuPont Pharmaceuticals and the Wistar Institute. Mr. Donover has held various research positions, including Cell Biologist at the ATCC, Research Lab Assistant at CWRU Ireland Cancer Center, and Research Laboratory Mechanic in the University of Chicago Chemistry Department.

 

Amanda Schabdach

Amanda Schabdach

Outreach Coordinator, Biomedical Research Assistant

Ms. Schabdach graduated from St. Mary's College of Maryland with a degree in Chemistry and Math and is currently enrolled in a Masters program at University of the Sciences in Philadelphia. A member of the LCGC team since 2007, Ms. Schabdach's primary job responsibilities include data analysis, marketing, and editorial work.